Oncotarget

Research Papers:

The prognostic value of histological subtype in patients with metastatic bladder cancer

Cheng Chen, Linkun Hu, Ye Chen and Jianquan Hou _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:28408-28417. https://doi.org/10.18632/oncotarget.16083

Metrics: PDF 967 views  |   HTML 1718 views  |   ?  


Abstract

Cheng Chen1,*, Linkun Hu1,*, Ye Chen1, Jianquan Hou1

1Department of Urology, the First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China

*These authors contributed equally to this work

Correspondence to:

Jianquan Hou, email: houjianquan@suda.edu.cn

Keywords: urinary bladder neoplasms, histology, distant metastasis, prognosis, survival

Received: December 14, 2016     Accepted: February 28, 2017     Published: March 10, 2017

ABSTRACT

We aim to evaluate the prognostic effect of the histological sub-type in patients with metastatic bladder cancer based on the Surveillance Epidemiology and End Results database. A total of 2634 eligible patients were included. The histological subtypes were: transitional cell carcinoma (TCC; 75.2%); adenocarcinoma (3.3%); squamous cell carcinoma (SQCC; 4.1%); and small cell carcinoma (4.3%). A significant association of adenocarcinoma with better survival outcomes (P < 0.015), and that of SQCC with worse outcomes (P < 0.001) was observed. On multivariate analysis, adenocarcinoma was significantly associated with longer and SQCC with shorter survival time as compared to TCC. Overall, 1331 (50.5%) patients had a single metastatic site and 523 (19.9%) had multiple sites involved. Single-site metastasis had a better survival outcome than multiple metastases (P < 0.001). Histological sub-type and presence of multiple metastatic sites are independent predictors of survival time. Prospective, in-depth research is needed to determine optimal therapeutic strategies for different histological subtypes of bladder cancer with different metastatic patterns.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16083